Yen Luu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yen Luu has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Joseph Han
Department of Dermatology Icahn School of Medicine at Mount Sinai New York New York USA
5 shared publications - Nicholas Gulati
Department of Dermatology Icahn School of Medicine at Mount Sinai New York New York USA
5 shared publications - Aneesh Agarwal
From the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
4 shared publications - Shayan Owji
Department of Dermatology Icahn School of Medicine at Mount Sinai New York New York USA
4 shared publications - Jonathan Ungar
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
3 shared publications - Brian J. Abittan
Department of Dermatology Icahn School of Medicine at Mount Sinai New York, NY United States
2 shared publications
Latest Publications
- 29 September 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (1) , 12-15
Risk for second primary cancers among pediatric and young adult melanoma survivors
Background/Objectives: Second primary cancers (SPCs) are a leading cause of morbidity and mortality among cancer survivors. In this study, we aimed to characterize the incidence of SPCs among pediatric and young adult survivors of CM.Methods: Using the Surveillance, Epidemiology, and End Results Program data spanning 2000–2018, we calculated standardized incidence ratios (SIR) to assess SPC risk in all pediatric (0–18 years) and young adult (19–29 years) patients with a first primary cancer diagnosis of CM.Results: Of 7,169 total CM survivors, 632 (8.82%) developed a SPC, corresponding to a 5‐fold increased risk (standardized incidence ratio [SIR] 4.98; 95% confidence interval [CI] 4.60–5.38) compared to the general population. There was a highly elevated risk for second primary melanoma across all age groups (SIR 32.5; 95% CI 29.7–35.6), constituting the majority of SPC diagnoses (N = 485). Infants diagnosed with CM before 1 year of age had the highest risk for any SPC (SIR 164; 95% CI 19.8–592) and young adults diagnosed at 25–29 years had the lowest risk (SIR 4.64; 95% CI 4.19–5.13). SPC incidence was highest within the first year of CM diagnosis (SIR 27.5; 95% CI 23.7–31.6) and progressively decreased with time.Conclusions: Variation exists in the incidence and type of SPC according to age among pediatric and young adult survivors of CM.
- 29 September 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (1) , 12-15
Risk for second primary cancers among pediatric and young adult melanoma survivors
Background/Objectives: Second primary cancers (SPCs) are a leading cause of morbidity and mortality among cancer survivors. In this study, we aimed to characterize the incidence of SPCs among pediatric and young adult survivors of CM.Methods: Using the Surveillance, Epidemiology, and End Results Program data spanning 2000–2018, we calculated standardized incidence ratios (SIR) to assess SPC risk in all pediatric (0–18 years) and young adult (19–29 years) patients with a first primary cancer diagnosis of CM.Results: Of 7,169 total CM survivors, 632 (8.82%) developed a SPC, corresponding to a 5‐fold increased risk (standardized incidence ratio [SIR] 4.98; 95% confidence interval [CI] 4.60–5.38) compared to the general population. There was a highly elevated risk for second primary melanoma across all age groups (SIR 32.5; 95% CI 29.7–35.6), constituting the majority of SPC diagnoses (N = 485). Infants diagnosed with CM before 1 year of age had the highest risk for any SPC (SIR 164; 95% CI 19.8–592) and young adults diagnosed at 25–29 years had the lowest risk (SIR 4.64; 95% CI 4.19–5.13). SPC incidence was highest within the first year of CM diagnosis (SIR 27.5; 95% CI 23.7–31.6) and progressively decreased with time.Conclusions: Variation exists in the incidence and type of SPC according to age among pediatric and young adult survivors of CM.
- Open Access
- 18 July 2023
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 9 (3) , e097
Vulvar allergens in topical preparations recommended on social media: a cross-sectional analysis of Facebook groups for lichen sclerosus
- 18 July 2023
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 9 (3) , e097
Open AccessVulvar allergens in topical preparations recommended on social media: a cross-sectional analysis of Facebook groups for lichen sclerosus
- 1 June 2023
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 159 (6) , 662-663
Pink, Dome-Shaped Papule of the Scalp in a Patient With Multiple Squamous Cell Carcinomas
A 74-year-old man with a history of multiple squamous cell carcinomas that were treated with Mohs micrographic surgery presented with a tender, enlarging scalp lesion of 6 months’ duration. Skin examination revealed a 5-mm bright pink, dome-shaped papule with overlying vessels located at the crown of the scalp (Figure, A). There was no purulent discharge or overlying skin changes. A shave skin biopsy was performed and submitted for histopathologic analysis (Figure, B-D).
- 1 June 2023
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 159 (6) , 662-663
Pink, Dome-Shaped Papule of the Scalp in a Patient With Multiple Squamous Cell Carcinomas
A 74-year-old man with a history of multiple squamous cell carcinomas that were treated with Mohs micrographic surgery presented with a tender, enlarging scalp lesion of 6 months’ duration. Skin examination revealed a 5-mm bright pink, dome-shaped papule with overlying vessels located at the crown of the scalp (Figure, A). There was no purulent discharge or overlying skin changes. A shave skin biopsy was performed and submitted for histopathologic analysis (Figure, B-D).
- 31 January 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 88 (6) , 1376-1378
Elevated body mass index, statin use, and cholecystectomy are associated with vulvar lichen sclerosus: A retrospective, case-control study
- 31 January 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 88 (6) , 1376-1378
Elevated body mass index, statin use, and cholecystectomy are associated with vulvar lichen sclerosus: A retrospective, case-control study
- 29 January 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (5) , 879-881
Ichthyosis, cataracts, and motor delay in an infant: A case of Chanarin–Dorfman syndrome
Chanarin-Dorfman syndrome (CDS) is a rare, autosomal recessive disorder of impaired triacylglycerol catabolism leading to cytoplasmic deposition of triglycerides in various cell types. We describe the case of an 8-month-old boy with cataracts, strabismus, motor delays, and an ichthyosiform rash since birth. Genetic testing revealed a pathogenic variant of the ABHD5 gene, suggestive of CDS, and further workup demonstrated hepatic steatosis and myopathy. His ichthyosis improved with initiation of a diet low in very long-chain fatty acids and medium-chain fatty acid supplementation.
- 29 January 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (5) , 879-881
Ichthyosis, cataracts, and motor delay in an infant: A case of Chanarin–Dorfman syndrome
Chanarin-Dorfman syndrome (CDS) is a rare, autosomal recessive disorder of impaired triacylglycerol catabolism leading to cytoplasmic deposition of triglycerides in various cell types. We describe the case of an 8-month-old boy with cataracts, strabismus, motor delays, and an ichthyosiform rash since birth. Genetic testing revealed a pathogenic variant of the ABHD5 gene, suggestive of CDS, and further workup demonstrated hepatic steatosis and myopathy. His ichthyosis improved with initiation of a diet low in very long-chain fatty acids and medium-chain fatty acid supplementation.
- Open Access
- 28 January 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (2) , 100179
Modulation of Inflammatory Proteins in Serum May Reflect Cutaneous Immune Responses in Cancer Immunotherapy
- 28 January 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (2) , 100179
Open AccessModulation of Inflammatory Proteins in Serum May Reflect Cutaneous Immune Responses in Cancer Immunotherapy
- 28 December 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (6) , 804-809
Unique protein signatures evolve during the course of a delayed‐type hypersensitivity reaction in human skin
Diphencyprone (DPCP) is a hapten that causes a delayed‐type hypersensitivity reaction when applied topically. It has clinical uses in the treatment of various conditions such as melanoma metastases, warts, and alopecia areata, but the mechanisms are currently not well understood in humans. To further characterize the immunologic effects of DPCP, the authors performed a proteomic analysis of normal skin of eight healthy volunteers following a single application of DPCP and compared them with placebo‐treated skin from the same volunteers. A total of 96 proteins were examined using the Olink immuno‐oncology panel at 3 days (peak response), 14 days (partially resolved response), and 120 days (completely resolved response). Our analysis revealed significant upregulation of markers of immune cell activation (interleukin [IL] 8), vascular and tissue remodeling (matrix metallopeptidase 12 [MMP12], nitric oxide synthase 3 [NOS3]), antineoplastic markers (granzyme B [GZMB]), and the Th1 axis (interferon gamma [IFNG], chemokine (C‐X‐C motif) ligand [CXCL] 9, CXCL10, CXCL11) at days 3 and 14 compared with placebo (p < 0.05). In addition, several negative regulators of immune function such as programmed cell death 1 (PD1), programmed cell death ligand 1 (PDL1) (p < 0.001), and lymphocyte activation gene 3 (LAG3) (p < 0.05) were significantly upregulated at days 3 and 14. This induction of negative regulators may explain the seemingly paradoxical therapeutic benefits of DPCP in autoimmune conditions such as alopecia areata. The current analysis also indicated IL‐4 upregulation only at day 3, followed by IL‐12 upregulation only at day 14, suggesting a transient Th2 response followed by Th1 polarization. Overall, these data suggest a complex and evolving immunological delayed‐type hypersensitivity response to a single application of DPCP over time. Future proteomic studies of samples from patients with melanoma metastases, warts, and alopecia areata treated long term with DPCP are needed to further evaluate its pharmacologic mechanisms.
- 28 December 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (6) , 804-809
Unique protein signatures evolve during the course of a delayed‐type hypersensitivity reaction in human skin
Diphencyprone (DPCP) is a hapten that causes a delayed‐type hypersensitivity reaction when applied topically. It has clinical uses in the treatment of various conditions such as melanoma metastases, warts, and alopecia areata, but the mechanisms are currently not well understood in humans. To further characterize the immunologic effects of DPCP, the authors performed a proteomic analysis of normal skin of eight healthy volunteers following a single application of DPCP and compared them with placebo‐treated skin from the same volunteers. A total of 96 proteins were examined using the Olink immuno‐oncology panel at 3 days (peak response), 14 days (partially resolved response), and 120 days (completely resolved response). Our analysis revealed significant upregulation of markers of immune cell activation (interleukin [IL] 8), vascular and tissue remodeling (matrix metallopeptidase 12 [MMP12], nitric oxide synthase 3 [NOS3]), antineoplastic markers (granzyme B [GZMB]), and the Th1 axis (interferon gamma [IFNG], chemokine (C‐X‐C motif) ligand [CXCL] 9, CXCL10, CXCL11) at days 3 and 14 compared with placebo (p < 0.05). In addition, several negative regulators of immune function such as programmed cell death 1 (PD1), programmed cell death ligand 1 (PDL1) (p < 0.001), and lymphocyte activation gene 3 (LAG3) (p < 0.05) were significantly upregulated at days 3 and 14. This induction of negative regulators may explain the seemingly paradoxical therapeutic benefits of DPCP in autoimmune conditions such as alopecia areata. The current analysis also indicated IL‐4 upregulation only at day 3, followed by IL‐12 upregulation only at day 14, suggesting a transient Th2 response followed by Th1 polarization. Overall, these data suggest a complex and evolving immunological delayed‐type hypersensitivity response to a single application of DPCP over time. Future proteomic studies of samples from patients with melanoma metastases, warts, and alopecia areata treated long term with DPCP are needed to further evaluate its pharmacologic mechanisms.
- Open Access
- 8 November 2022
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 5 (4) , e42345
Medicare Opt-Out Trends Among Dermatologists May Reflect Systemic Health Policy: Cross-sectional Analysis
Background: Provider opt-out of accepting Medicare insurance is a nationally tracked metric by the Centers for Medicare & Medicaid Services (CMS) for all physicians, including dermatologists. Although this usually only consists of a small number of providers, the magnitude of opting out has varied historically, often tracing changes in systemic health care policy. Objective: In this paper, we explored dermatologist opt-out data since 2001, as reported by the CMS, to characterize trends and provide evidence that shifts in provider opt-out may represent a potential indicator of the state of health policy and possible needs for reform as it pertains to Medicare. Methods: The publicly available Opt Out Affidavits data set, available from the CMS, was evaluated for providers in all dermatologic specialties from January 1, 2001, to May 27, 2022. Results: There were a total of 196 dermatology opt-outs in the overall period, with the largest spike being 33 providers in 2016, followed by generally consistent decreases through 2021. In the most recent 12 months of data, the number of new monthly opt-outs from January 2022 to May 2022 was significantly higher than that of the trailing 7 months of 2021 (P=.03). Conclusions: Despite decreasing numbers of dermatologist opt-outs in the late-2010s, 2022 was marked by a significant increase in opt-outs. The reduced acceptance of Medicare by dermatologists may present risks to care access, so it is important to frequently assess physician opt-out data and changes over time.
- 8 November 2022
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 5 (4) , e42345
Open AccessMedicare Opt-Out Trends Among Dermatologists May Reflect Systemic Health Policy: Cross-sectional Analysis
Background: Provider opt-out of accepting Medicare insurance is a nationally tracked metric by the Centers for Medicare & Medicaid Services (CMS) for all physicians, including dermatologists. Although this usually only consists of a small number of providers, the magnitude of opting out has varied historically, often tracing changes in systemic health care policy. Objective: In this paper, we explored dermatologist opt-out data since 2001, as reported by the CMS, to characterize trends and provide evidence that shifts in provider opt-out may represent a potential indicator of the state of health policy and possible needs for reform as it pertains to Medicare. Methods: The publicly available Opt Out Affidavits data set, available from the CMS, was evaluated for providers in all dermatologic specialties from January 1, 2001, to May 27, 2022. Results: There were a total of 196 dermatology opt-outs in the overall period, with the largest spike being 33 providers in 2016, followed by generally consistent decreases through 2021. In the most recent 12 months of data, the number of new monthly opt-outs from January 2022 to May 2022 was significantly higher than that of the trailing 7 months of 2021 (P=.03). Conclusions: Despite decreasing numbers of dermatologist opt-outs in the late-2010s, 2022 was marked by a significant increase in opt-outs. The reduced acceptance of Medicare by dermatologists may present risks to care access, so it is important to frequently assess physician opt-out data and changes over time.
- 7 October 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (4) , 588-595.e3
Risk of Nonkeratinocyte Skin Cancers in People Living with HIV during the Era of Antiretroviral Therapy
- 7 October 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (4) , 588-595.e3
Risk of Nonkeratinocyte Skin Cancers in People Living with HIV during the Era of Antiretroviral Therapy
- Open Access
- 13 May 2022
- Published by Elsevier in JAAD Case Reports
- Vol. 25, 30-34
Epidemiology, clinicopathology, and diagnosis of cutaneous nocardiosis: A case series and population-level analysis
- 13 May 2022
- Published by Elsevier in JAAD Case Reports
- Vol. 25, 30-34
Open AccessEpidemiology, clinicopathology, and diagnosis of cutaneous nocardiosis: A case series and population-level analysis